Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

T. M. Beer, W. C. Pierce, B. A. Lowe, W. D. Henner

Research output: Contribution to journalArticlepeer-review

178 Scopus citations

Abstract

Background: This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain. Patients and methods: Twenty-five patients were treated with docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment. This eight-week treatment cycle was repeated until progression or unacceptable toxicity. Endpoints included palliative response (a 2-point reduction on the 6-point Present Pain Intensity scale without an increase in analgesic consumption or a 50% decrease in analgesic use without an increase in pain), PSA response (a 50% decrease maintained at least four weeks), measurable disease response, survival, and toxicity. Results: Twelve of 25 patients (48%, 95% confidence interval (95% CI): 28%-68%) had a palliative response. Eleven of the 24 patients who entered with an elevated PSA (46%, 95% CI: 25%-67%) had a PSA response. Two of five patients with measurable disease had a partial response. Toxicity of therapy was modest with no treatment-related mortality. Twenty-five percent of patients experienced a grade 3 or 4 hematologic toxicity and 36% of patients experienced a grade 3 non-hematologic toxicity. Conclusions: Weekly docetaxel is well tolerated in patients with androgen-independent prostate cancer and has significant activity as measured by relief of pain, reduction in PSA, and reduction in measurable disease.

Original languageEnglish (US)
Pages (from-to)1273-1279
Number of pages7
JournalAnnals of Oncology
Volume12
Issue number9
DOIs
StatePublished - 2001

Keywords

  • Adenocarcinoma of the prostate
  • Chemotherapy
  • Docetaxel
  • Prostate cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer'. Together they form a unique fingerprint.

Cite this